Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug
Biocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this (...)
Site référencé: The Economic Times
The Economic Times
Tankup Engineers IPO opens for subscription. Check key dates, price band, GMP and other details
23/04/2025
IT bore brunt of FPI pullout in April amid tariff turmoil
23/04/2025
Experts suggest investors to accumulate precious metal, but follow asset allocation
23/04/2025
Ather Energy set to launch Rs 3,000-cr IPO on April 28
23/04/2025
Gold tops Rs 1,00,000 with a little help From Trump
23/04/2025
SGB buyers may eye profits, but experts feel a hold's better
23/04/2025
